Could Polynovo shares get kicked out of the ASX 200?

Is Polynovo really in danger of getting kicked out of the ASX 200?

| More on:
A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ASX healthcare share Polynovo has had a rough time of it lately
  • The company is now down almost 40% in 2022 alone so far
  • But Polynovo could be about to get kicked out of the ASX 200 as well

What a time it has been for the Polynovo Ltd (ASX: PNV) share price lately. Polynovo shares are currently having a so-so day on the ASX boards today. The healthcare company is presently down 0.54% at 92 cents a share after earlier hitting an intraday high of 96.5 cents a share.

But zooming out, the picture looks a lot bleaker. This company is still down by a hefty 39.7% over 2022 alone. Since this time last year, the Polynovo share price has lost almost 70% of its value. And let's not even discuss Polynovo's all-time high near $4 a share that we saw back in December 2020.

Polynovo's falls now put this company at a market capitalisation well under $1 billion. In fact, it is sitting at just over $608 million today. That puts Polynovo at serious risk of getting kicked out of the S&P/ASX 200 Index (ASX: XJO).

The ASX 200 is the flagship index of the Australian share market. But it only holds 200 of the largest ASX shares by market capitalisation. Thus, if Polynovo's fortunes don't improve significantly over the next month or so, the company could find itself well outside the ASX's 200 largest companies and, thus, be excluded from the index when it is next rebalanced.

Could Polynovo shares be kicked out of the ASX 200?

This view was argued in a recent article in The Australian. According to the report, broker Wilsons is picking coal miner Coronado Global Resources Inc (ASX: CRN), lithium stock Core Lithium Ltd (ASX: CXO) and tech company Brainchip Holdings Ltd (ASX: BRN) as the next entrants into the ASX 200. That's largely thanks to significant share price appreciation in recent months.

But if these ASX up-and-comers join the index, they will need to take the places of other ASX shares. Wilsons is, indeed, predicting that Polynovo could well be one of the losers, along with other shares like Tyro Payments Ltd (ASX: TYR) and Appen Ltd (ASX: APX).

Removal from an index like the ASX 200 has little effect on the company itself. However, it can result in share price selling pressure. Many ASX fund managers have mandates that dictate they can only hold ASX 200 shares. What's more, any index funds that track the ASX 200 (of which there are many) would immediately sell out of a Polynovo position if the company was kicked out of the index. These two factors mean ASX 200 exclusion often results in selling pressure on a company's share price.

Going off Polynovo's recent share price performance, that's probably the last thing investors need to hear right now. But such is ASX life.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Appen Ltd, POLYNOVO FPO, and Tyro Payments. The Motley Fool Australia has recommended Tyro Payments. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »